首页> 外文期刊>Diabetes, metabolic syndrome and obesity: targets and therapy >Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
【24h】

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway

机译:利拉鲁肽对脂肪分解和AC3 / PKA / HSL途径的影响

获取原文
       

摘要

Background: Liraglutide reduces blood glucose, body weight and blood lipid levels. Hormone-sensitive lipase (HSL) is a key enzyme in lipolysis. Evidence from our and other studies have demonstrated that adenylate cyclase 3 (AC3) is associated with obesity and can be upregulated by liraglutide in obese mice. In the present study, we investigated whether hepatic HSL activity is regulated by liraglutide and characterized the effect of liraglutide in the AC3/protein kinase A (PKA)/HSL signalling pathway. Methods: Obese mice or their lean littermates were treated with liraglutide or saline for 8?weeks. Serum was collected for the measurement of insulin and lipids. We investigated hepatic AC3, HSL and phosphorylated HSL Ser-660 (p-HSL(S660)) protein expression levels andAC3 and HSL mRNA expression levels and cyclic adenosine monophosphate (cAMP), PKA activity in liver tissue. Results: Liraglutide treatment decreased triglycerides (TGs) and free fatty acids (FFAs), increased glycerol, and upregulated hepatic AC3 and p-HSL(s660) levels and cAMP and PKA activities. Conclusion: The results suggest that liraglutide can upregulates AC3/PKA/HSL pathway and may promotes lipolysis.
机译:背景:利拉鲁肽可降低血糖,体重和血脂水平。激素敏感性脂肪酶(HSL)是脂解中的关键酶。我们的研究和其他研究的证据表明,腺苷酸环化酶3(AC3)与肥胖症相关,并且在肥胖小鼠中利拉鲁肽可以上调腺苷酸环化酶3的表达。在本研究中,我们调查了肝HSL活性是否受利拉鲁肽调节,并表征了利拉鲁肽在AC3 /蛋白激酶A(PKA)/ HSL信号通路中的作用。方法:用利拉鲁肽或生理盐水处理肥胖小鼠或其瘦仔猪8周。收集血清以测量胰岛素和脂质。我们研究了肝组织中肝AC3,HSL和磷酸化的HSL Ser-660(p-HSL(S660))蛋白表达水平以及AC3和HSL mRNA表达水平以及环磷酸腺苷(cAMP),PKA活性。结果:利拉鲁肽治疗降低了甘油三酸酯(TGs)和游离脂肪酸(FFA),甘油升高,并上调了肝AC3和p-HSL(s660)水平以及cAMP和PKA活性。结论:结果表明利拉鲁肽可以上调AC3 / PKA / HSL途径,并可能促进脂肪分解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号